Oramed Pharmaceuticals ORMP Income Statement (2009-2026)

NASDAQ ORMP
$3.97 -0.03 (-0.75%)
At close: Nov 10, 2026 · 4:00 PM EST
Reported Financials

Oramed Pharmaceuticals Quarterly Income Statement

Periods 70 quarters
Latest Jun 2026

Oramed Pharmaceuticals reported net income of $78.16M for the quarter ended Jun 2026. This income statement covers 70 quarters of results from Feb 2009 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Feb2009 May2009 Aug2009 Nov2009 Feb2010 May2010 Aug2010 Nov2010 Feb2011 May2011 Aug2011 Nov2011 Feb2012 May2012 Aug2012 Nov2012 Feb2013 May2013 Aug2013 Nov2013 Feb2014 May2014 Aug2014 Nov2014 Feb2015 May2015 Aug2015 Nov2015 Feb2016 May2016 Aug2016 Nov2016 Feb2017 May2017 Aug2017 Nov2017 Feb2018 May2018 Aug2018 Nov2018 Feb2019 May2019 Aug2019 Nov2019 Feb2020 May2020 Aug2020 Nov2020 Feb2021 May2021 Aug2021 Nov2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue
0.67M0.67M0.68M0.90M0.67M0.67M2.00M
Cost of RevenueCost of Rev
1.99M
Gross Profit
0.01M
Operating items
Research & DevelopmentR&D
6.41M5.84M9.18M5.35M9.04M4.43M1.82M0.96M1.77M1.18M1.44M2.24M1.46M2.21M1.03M1.15M1.99M1.59M
Selling, General & AdministrativeSG&A
1.74M5.49M2.53M3.06M2.73M1.26M2.45M2.60M2.11M1.78M1.69M0.85M2.13M2.31M1.46M1.27M3.68M2.07M2.77M
Other Operating ExpensesOther Opex
5.49M3.30M1.26M
Operating ExpensesOpex
8.15M11.33M11.71M8.41M11.76M5.69M4.27M3.56M3.88M2.96M3.14M3.09M3.60M4.51M2.49M2.43M5.67M3.66M2.77M
Operating IncomeOp. Inc
8.06M-11.25M-11.42M-8.19M-12.33M-5.21M-3.79M-2.89M-3.88M-2.96M-3.14M-3.09M-3.60M-4.50M-2.49M-2.43M-5.67M-3.66M-2.77M
Non-operating items
Non Operating Interest Expenses
0.18M0.09M0.83M1.21M0.59M0.26M
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
Interest & Investment IncomeInt & Inv Inc
0.54M0.35M0.16M1.60M2.48M0.65M0.28M
Other Non Operating IncomeOther Non Op Inc.
-0.14M0.54M0.16M3.55M16.65M-20.09M0.12M-0.26M32.28M-39.43M-0.15M0.00M
Non Operating IncomeNon Op. Inc.
0.20M-0.04M0.54M0.35M1.04M1.00M1.60M2.48M0.44M18.38M5.09M14.23M-15.42M-6.19M-2.56M15.37M61.47M15.18M44.85M103.74M
Net income details
EBIT
8.06M-11.25M-11.42M-8.19M-12.33M-5.21M-3.79M-2.89M-3.88M-2.96M-3.14M-3.09M-3.60M-4.50M-2.49M-2.43M-5.67M-3.66M-2.77M
EBT
7.89M-10.71M-11.07M-7.15M-12.26M-3.61M-1.31M-3.28M13.30M1.53M10.84M-18.51M-9.78M-7.06M13.13M59.45M9.80M49.44M101.59M
Tax ProvisionsTaxes
0.10M1.63M1.13M0.42M0.58M-0.13M11.06M-0.21M11.13M23.43M
Income After Tax
7.89M-10.71M-11.07M-7.25M-12.26M-3.61M-1.31M-3.28M13.30M1.53M9.20M-19.64M-10.20M-7.64M13.26M48.39M10.01M38.31M78.16M
Income from Continuing OperationsIncome (Continuing)
7.89M-10.71M-11.07M-7.25M-12.26M-3.61M-1.31M-3.28M13.30M1.53M9.20M-19.64M-10.20M-7.64M13.26M48.39M10.01M38.31M78.16M
Consolidated Net IncomeConsol Net Inc.
-5.48M7.89M-10.71M-11.07M-7.25M-12.26M-3.61M-1.31M-3.28M13.73M1.53M9.20M-19.64M-10.20M-7.64M13.26M48.39M10.01M38.31M78.16M
Net Income Attributable to Noncontrolling InterestsNCI Net Income
0.21M-0.28M-0.53M-0.19M-0.19M-0.22M-0.12M-0.06M0.83M0.00M-0.01M-0.02M-0.01M-0.03M-0.01M
Income towards Parent CompanyParent Net Inc
-5.48M8.10M-10.71M-10.53M-7.06M-8.54M-3.40M-1.19M-3.22M12.90M1.54M9.21M-19.62M-10.19M-7.64M13.29M48.40M10.01M38.31M78.16M
Net Income towards Common StockholdersNet Income
-5.48M7.89M-10.43M-10.53M-7.06M-11.67M-3.40M-1.19M-3.22M12.90M1.54M9.21M-19.62M-10.19M-7.64M13.29M48.40M10.01M38.31M78.16M
Additional items
EPS (Basic)
-0.190.22-0.27-0.27-0.18-0.30-0.08-0.03-0.080.320.040.22-0.48-0.25-0.190.321.160.240.941.90
EPS (Diluted)
-0.190.23-0.27-0.27-0.18-0.30-0.08-0.03-0.080.320.040.22-0.48-0.25-0.190.311.130.240.911.84
Shares Outstanding
28.47M36.67M38.68M38.80M39.10M39.00M40.04M40.23M40.45M40.32M40.84M40.96M40.90M40.83M41.23M41.74M41.76M41.40M40.77M41.04M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
28.47M34.54M38.68M38.80M39.10M39.00M40.04M40.23M40.45M40.57M41.56M41.59M40.90M40.83M41.23M42.61M42.77M42.42M41.97M42.50M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
28.47M38.09M38.56M38.56M39.11M39.56M39.97M40.22M40.28M40.34M40.52M40.63M40.21M39.92M40.85M40.85M40.84M39.28M40.93M41.31M
EBITDA
8.07M-11.24M-11.40M-8.17M-12.31M-5.17M-3.74M-2.84M-3.82M-2.91M-3.08M-3.04M-3.56M-4.47M-2.46M-2.40M-5.64M-3.63M-2.74M
Interest ExpensesInt Expense
0.18M0.09M0.83M1.21M0.59M0.26M
Tax Rate
15.08%18.61%22.51%23.06%

Oramed Pharmaceuticals Income Statement API

Pull Oramed Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=ORMP&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY